Giacomo Masserdotti

Dr. Giacomo Masserdotti

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Neuron
Verified
Journal Article
Closed access
RBRiccardo Bocchi
Riccardo Bocchi
GMGiacomo Masserdotti
Giacomo Masserdotti
MGMagdalena Götz
Magdalena Götz

2 July 2024 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
APAllwyn Pereira
Allwyn Pereira
JDJeisimhan Diwakar
Jeisimhan Diwakar
GMGiacomo Masserdotti
Giacomo Masserdotti
SBSude Beşkardeş
Sude Beşkardeş
TSTatiana Simon
Tatiana Simon
MGMagdalena Götz
Magdalena Götz
Direct neuronal reprogramming is a promising approach to regenerate neurons from local glial cells. However, mechanisms of epigenome remodeling and co-factors facilitating this process are unclear. In this study, we combined single-cell multiomics with genome-wide profiling of three-dimensional nuclear architecture and DNA methylation in mouse astrocyte-to-neuron reprogramming mediated by Neurogenin2 (Ngn2) and its phosphorylation-resistant form (PmutNgn2), respectively. We show that Ngn2 drives multilayered chromatin remodeling at dynamic enhancer–gene interaction sites. PmutNgn2 leads to higher reprogramming efficiency and enhances epigenetic remodeling associated with neuronal maturation. However, the differences in binding sites or downstream gene activation cannot fully explain this effect. Instead, we identified Yy1, a transcriptional co-factor recruited by direct interaction with Ngn2 to its target sites. Upon deletion of Yy1, activation of neuronal enhancers, genes and ultimately reprogramming are impaired without affecting Ngn2 binding. Thus, our work highlights the key role of interactors of proneural factors in direct neuronal reprogramming.

8 December 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SSSwetlana Sirko
Swetlana Sirko
CSChristian Schichor
Christian Schichor
PVPatrizia Della Vecchia
Patrizia Della Vecchia
FMFabian Metzger
Fabian Metzger
GSGiovanna Sonsalla
Giovanna Sonsalla
MGMagdalena Götz
Magdalena Götz
The glial environment influences neurological disease progression, yet much of our knowledge still relies on preclinical animal studies, especially regarding astrocyte heterogeneity. In murine models of traumatic brain injury, beneficial functions of proliferating reactive astrocytes on disease outcome have been unraveled, but little is known regarding if and when they are present in human brain pathology. Here we examined a broad spectrum of pathologies with and without intracerebral hemorrhage and found a striking correlation between lesions involving blood–brain barrier rupture and astrocyte proliferation that was further corroborated in an assay probing for neural stem cell potential. Most importantly, proteomic analysis unraveled a crucial signaling pathway regulating this astrocyte plasticity with GALECTIN3 as a novel marker for proliferating astrocytes and the GALECTIN3-binding protein LGALS3BP as a functional hub mediating astrocyte proliferation and neurosphere formation. Taken together, this work identifies a therapeutically relevant astrocyte response and their molecular regulators in different pathologies affecting the human cerebral cortex.

1 July 2023 in Hypertension
Verified
Journal Article
Closed access
SGSiyuan Gong
Siyuan Gong
NSNa Sun
Na Sun
LMLucie S. Meyer
Lucie S. Meyer
MTMartina Tetti
Martina Tetti
CKChristina Koupourtidou
Christina Koupourtidou
TWTracy Williams
Tracy Williams
Background: Primary aldosteronism is frequently caused by an adrenocortical aldosterone-producing adenoma (APA) carrying a somatic mutation that drives aldosterone overproduction. APAs with a mutation in KCNJ5 (APA- KCNJ5 MUT ) are characterized by heterogeneous CYP11B2 (aldosterone synthase) expression, a particular cellular composition and larger tumor diameter than those with wild-type KCNJ5 (APA- KCNJ5 WT ). We exploited these differences to decipher the roles of transcriptome and metabolome reprogramming in tumor pathogenesis. Methods: Consecutive adrenal cryosections (7 APAs and 7 paired adjacent adrenal cortex) were analyzed by spatial transcriptomics (10x Genomics platform) and metabolomics (in situ matrix-assisted laser desorption/ionization mass spectrometry imaging) co-integrated with CYP11B2 immunohistochemistry. Results: We identified intratumoral transcriptional heterogeneity that delineated functionally distinct biological pathways. Common transcriptomic signatures were established across all APA specimens which encompassed 2 distinct transcriptional profiles in CYP11B2-immunopositive regions ( CYP11B2 -type 1 or 2). The CYP11B2 -type 1 signature was characterized by zona glomerulosa gene markers and was detected in both APA- KCNJ5 MUT and APA- KCNJ5 WT . The CYP11B2 -type 2 signature displayed markers of the zona fasciculata or reticularis and predominated in APA- KCNJ5 MUT . Metabolites that promote oxidative stress and cell death accumulated in APA- KCNJ5 WT . In contrast, antioxidant metabolites were abundant in APA- KCNJ5 MUT . Finally, APA-like cell subpopulations—negative for CYP11B2 gene expression—were identified in adrenocortical tissue adjacent to APAs suggesting the existence of tumor precursor states. Conclusions: Our findings provide insight into intra- and intertumoral transcriptional heterogeneity and support a role for prooxidant versus antioxidant systems in APA pathogenesis highlighting genotype-dependent capacities for tumor expansion.

23 January 2024 in Neuron
Verified
Journal Article
Open access
GSGiovanna Sonsalla
Giovanna Sonsalla
AMAna Belen Malpartida
Ana Belen Malpartida
TRTherese Riedemann
Therese Riedemann
MGMirjana Gusic
Mirjana Gusic
EREjona Rusha
Ejona Rusha
GMGiacomo Masserdotti
Giacomo Masserdotti
Mitochondria account for essential cellular pathways, from ATP production to nucleotide metabolism, and their deficits lead to neurological disorders and contribute to the onset of age-related diseases. Direct neuronal reprogramming aims at replacing neurons lost in such conditions, but very little is known about the impact of mitochondrial dysfunction on the direct reprogramming of human cells. Here, we explore the effects of mitochondrial dysfunction on the neuronal reprogramming of induced pluripotent stem cell (iPSC)-derived astrocytes carrying mutations in the NDUFS4 gene, important for Complex I and associated with Leigh syndrome. This led to the identification of the unfolded protein response as a major hurdle in the direct neuronal conversion of not only astrocytes and fibroblasts from patients but also control human astrocytes and fibroblasts. Its transient inhibition potently improves reprogramming by influencing the mitochondria-endoplasmic-reticulum-stress-mediated pathways. Taken together, disease modeling using patient cells unraveled novel general hurdles and ways to overcome these in human astrocyte-to-neuron reprogramming.

23 August 2024 in Cells
Verified
Journal Article
Open access
PDF file
MPMatteo Puglisi
Matteo Puglisi
CLChu Lan Lao
Chu Lan Lao
GWGulzar Wani
Gulzar Wani
GMGiacomo Masserdotti
Giacomo Masserdotti
RBRiccardo Bocchi
Riccardo Bocchi
MGMagdalena Götz
Magdalena Götz
Direct neuronal reprogramming is a promising approach to replace neurons lost due to disease via the conversion of endogenous glia reacting to brain injury into neurons. However, it is essential to demonstrate that the newly generated neurons originate from glial cells and/or show that they are not pre-existing endogenous neurons. Here, we use controls for both requirements while comparing two viral vector systems (Mo-MLVs and AAVs) for the expression of the same neurogenic factor, the phosphorylation-resistant form of Neurogenin2. Our results show that Mo-MLVs targeting proliferating glial cells after traumatic brain injury reliably convert astrocytes into neurons, as assessed by genetic fate mapping of astrocytes. Conversely, expressing the same neurogenic factor in a flexed AAV system results in artefactual labelling of endogenous neurons fatemapped by birthdating in development that are negative for the genetic fate mapping marker induced in astrocytes. These results are further corroborated by chronic live in vivo imaging. Taken together, the phosphorylation-resistant form of Neurogenin2 is more efficient in reprogramming reactive glia into neurons than its wildtype counterpart in vivo using retroviral vectors (Mo-MLVs) targeting proliferating glia. Conversely, AAV-mediated expression generates artefacts and is not sufficient to achieve fate conversion.